EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Engineering the Future of Pneumococcal Conjugate Vaccines (PCV)
PhD, Chemical and Biotechnology, Savitribai Phule Pune University. Manager-Manufacturing, Inventprise Inc
Walmik Karbhari Gaikwad PhD is a seasoned biopharmaceutical expert with years in vaccine RD and manufacturing His PhD research pioneered costeffective processes for pneumococcal conjugate vaccines holds scholarly publications international patents and serves on editorial boards Based in Seattle currently works on cGMPcompliant process development and production at Inventprise Inc
Articles
Machine Learning for New Drugs
Common health problems such as obesity typediabetes hypertension and heart problems are caused by the effect of multiple genes environmental factors as well as lifestyle habits are called complex diseases A major risk factor for these diseases is hyperlipidemia or high lipid levels which is a complex disorder leading to increased level
Research Insights
Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study
Abstract Background Transarterial chemoembolization TACE and sorafenib are the therapeutic standard for intermediate and advanced stage hepatocellular carcinoma HCC patients respectively High costs with adverse events AE of sorafenib might limit sorafenib dosage further affecting therapeutic response To at
Case Studies
Bioavailability of Methadone After Sleeve Gastrectomy: A Planned Observational Case Study
Abstract Although there are no absolute contraindications to bariatric surgery most bariatric surgeons consider that patients with ongoing illicit drug use should not undergo such procedures The lack of clear recommendations within this field makes morbidly obese patients on opioidreplacement therapy a subgroup at risk for treatment refusal There is little
Techno Trends
China's New Regulatory Framework to Accelerate Biopharma R&D Investments
Chinas revised regulations aim to boost biopharma RD investments and streamline approval processes
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Lipid Based Drug Delivery Systems
Venu Madhav Katla working as Professor in Department of Pharmaceutics and having over 15 years of teaching and research experience. He had more than 15 research and review publications. He is having 10 national as well as international presentations in his credit. He guided around 25 M.Pharm and one Ph.D student (Pursuing).
Sridhar Babu Gummadi working as Professor and having over 18 years of teaching and research experience. He is having more than 20 research and review publications. Had 10 national as well as international presentations in his credit. He had one patent and one book as publication. He guided around 35 M.Pharm and 4 Ph.D students (Pursuing).
Somnath De working as Professor and have over 15 years of teaching and research experience. He had more than 20 research and review publications. He is having 10 national as well as international presentations in his credit. He filed one patent. He guided around 24 MPharm and 4 Ph.D students (Pursuing).
Moving from Code to Consequence
Dr. Sanjesh Kumar is an Assistant Professor at Chandigarh University Uttar Pradesh with a Ph.D. in Pharmacology. An award-winning academician specialized in neurodegenerative disorders and advanced drug delivery, he has authored over 45 high-impact publications and holds multiple patents, seamlessly bridging the gap between clinical research and classroom education.
Dr. Disha Marwaha earned a Ph.D. in Biological Sciences from the CSIR-Central Drug Research Institute (CSIR-CDRI) in 2024 and currently serves as an Assistant Professor at Chandigarh University Uttar Pradesh. Her research encompasses nanomedicine, pharmacokinetics, formulation development, and targeted drug delivery systems. She has authored more than 22 articles in peer-reviewed international journals.
A Structured Review on BCRP-Mediated Multidrug Resistance
Nensi Raytthatha Research Scholar, Sigma Institute of Pharmacy, Vadodara. She has published more than 5 research and review papers in reputed journals. She has presented more than 10 posters and have attended national and international conferences.
Isha Shah, Research Scholar, Sigma Institute of Pharmacy, Vadodara. She has published five research and review papers in reputed journals. She has presented more than 10 posters and have attended national and international conferences.
Jigar Vyas has more than 16 years of teaching and research experience. He has guided more than 40 PG students and has published more than 50 research and review papers. He has received of IQAC award for quality, performance in teaching and research.
Nano-Carrier based Smart Drug Delivery Systems
Sidharth Mehta, Researcher in Market Research domain at Prescient Healthcare Group, India. He is a Master’s in Pharmacy (Pharmaceutics) by qualification did his postgraduation from GJUS&T, Hisar, India. His research interests are mainly in the field of nanotechnology. In 2021, he spent a period at University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh (India) with an UGC-NRC project on “Development and Evaluation of Solid Lipid Nanoparticles as Drug Carrier for Topical Delivery of Leflunomide”. He has published several papers in international peer reviewed journals. He had done in-plant training in two pharmaceutical companies and improved his research skill as per industry standards. He worked hard on both his academic and practical skills, as a result of that he qualified national level pharmacy graduate test (GPAT) thrice and NIPER with good rank.
Nikita Yadav, she believes that you can achieve anything at any age. She is a Master’s in Pharmacy (Pharmaceutics) by qualification did her postgraduation from GJUS&T, Hisar, India. Her research interests are mainly in the field of nano- and micro-technology with the use of essentials and natural ingredients. She had many recent experiences like a course in Elsevier[Certified peer reviewer Course], in Good Clinical Practice by NIDA Clinical trials networkandin Regulatory affairs by Udemy.Also, she joined an NGO i.e., Aashman Foundation, which mainly work unconditionally on women empowerment, single income families and underprivileged children through relevant healthcare, innovative education, and environmental based livelihood programs. She also qualified national level pharmacy graduate test (GPAT) in 2020.
Smart Polymeric Nanocomposites for Cancer Therapeutics
Saurabh Shivalkar is a research fellow at Department of Applied Sciences, IIIT Allahabad, India. He did his M. Tech (Biomedical Engineering) from IIIT Allahabad. He has recently filed patent and published multiple papers in the allied areas of biomedical engineering and nanobiotechnology.
Sneha Ranjan is currently pursuing M.Sc. (Biotechnology) at Department of Biotechnology of Babasaheb Bhimrao Ambedkar University, Lucknow. She has worked on projects such as purification and characterisation of enzyme, production of recombinant proteins for diagnostics and therapeutics. She is currently working on polymeric nanocomposites for cancer therapeutics.
press releasesRead more...
Enhertu approved in the EU as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer
AstraZeneca and Daiichi Sankyos Enhertu trastuzumab deruxtecan has been approved in the European Union EU as a monotherapy for the adjuvant treatment of adult patients with resected HERpositive breast cancer who have residual invasive disease after neoadjuvant taxanebased and HERtargeted treatment
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
Teva Pharmaceuticals International GmbH a subsidiary of Teva Pharmaceutical Industries Ltd today announced that it has completed the acquisition of assets from BioXcel Therapeutics Inc including worldwide rights to BXCL BXCL is an investigational dexmedetomidine
Ferring Pharmaceuticals and Gameto sign agreement for proposed acquisition
Ferring Pharmaceuticals and Gameto today announced that they have signed an agreement for a global transaction under which Ferring would acquire Gameto Completion remains subject to customary and other closing conditions Until closing the companies will continue to operate independently
Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma
Innovent Biologics Inc a worldclass biopharmaceutical company that develops manufactures and commercializes high quality medicines for the treatment of cancer metabolic autoimmune and other major diseases today announced that a New Indication Application for sintilimab in combination with Nolgileuce...
Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent
The Menarini Group Menarini a leading international pharmaceutical and diagnostics company and Stemline Therapeutics Inc Stemline a whollyowned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients along with Georgiamune Inc a clinicalstage biot...
Aptar Pharma Acquires Pulmotree, Expanding Growth Opportunities in Next-Generation Pulmonary Drug
Aptar Pharma a global leader in drug delivery dosing protection technologies and services today announced the strategic acquisition of PULMOTREE a Munich Germanybased life science company specializing in pulmonary drug delivery systems for targeted delivery to the lungs The acquisition is expected t...
EventsRead more...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
LATEST NEWSRead more...
Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044
Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...
Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia
Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement
Pfizer’s TALZENNA Plus XTANDI Approved for Earlier Treatment of Metastatic Prostate Cancer
Pfizer has received approval from the US Food and Drug Administration FDA to expand the use of TALZENNA talazoparib in combination with XTANDI enzalutamide for men with metastatic prostate cancer that is sensitive to hormone treatment and has specific homologous recombination repair HRR gene mutatio...
Okomera Signs Agreement with Servier for Cancer Research Technology
Okomera has signed a commercial agreement with Servier to support the development of new cancer treatments using its tumour miniaturisation technology More than of oncology drug candidates fail to reach the market making it important to identify promising treatments at an early stage Okomeras platf...
AstraZeneca and Oracle Launch Global AI Collaboration to Optimise Clinical Trials
AstraZeneca and Oracle Health and Life Sciences have launched a global collaboration to use artificial intelligence AI realworld data and cloud technology to improve clinical trial efficiency and patient outcomes The collaboration will combine AstraZenecas expertise in drug development clinical rese...
UCB Receives Approval for ZILBRYSQ Autoinjector for Adults with Generalised Myasthenia Gravis
UCB has received approval from the US Food and Drug Administration FDA for a new autoinjector option for ZILBRYSQ zilucoplan a treatment for adults with generalised myasthenia gravis gMG who test positive for antiacetylcholine receptor AChR antibodies